| Israël | Turquie | Espagne | |
| Vaccination | de $100 | de $50 | de $50 |
| Traitement médicamenteux de l'épilepsie | de $3,200 | de $500 | de $400 |
| Traitement du sang de cordon ombilical | de $14,500 | de $5,000 | de $7,500 |
| Traitement de l'autisme | de $9,500 | de $2,000 | de $3,000 |
| Thérapie Vojta | de $1,800 | de $200 | de $150 |
Bookimed ne rajoute pas de frais pour les traitements de Pédiatrie. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Pédiatrie et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Pédiatrie.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.
He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.
He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.
Dr. David (Dudi) Mishali, MD, is Director of Pediatric and Congenital Cardiothoracic Surgery at Sheba Medical Center. He treats infants and children with congenital heart defects. His work includes rare, high-risk anomalies and complex newborn reconstructions.
He trained internationally. He completed his residency at Rabin Medical Center and clinical fellowships in cardiac surgery at the Cleveland Clinic and in congenital pediatric cardiothoracic surgery at UCSF. He is board certified in cardiothoracic surgery. He developed and implemented minimally invasive methods that reduce surgical trauma and improve cosmetic results.
He is a Senior Lecturer at Tel Aviv University’s Sackler Faculty of Medicine. He has written many peer-reviewed papers and book chapters, including on point-of-care testing in children during cardiopulmonary bypass and on accessory mitral valve tissue. He holds a leadership role at a hospital ranked among the world’s top 10.